MA46959A - Cellules b modifiées et compositions et méthodes associées - Google Patents

Cellules b modifiées et compositions et méthodes associées

Info

Publication number
MA46959A
MA46959A MA046959A MA46959A MA46959A MA 46959 A MA46959 A MA 46959A MA 046959 A MA046959 A MA 046959A MA 46959 A MA46959 A MA 46959A MA 46959 A MA46959 A MA 46959A
Authority
MA
Morocco
Prior art keywords
cells
modified
methods
related compositions
compositions
Prior art date
Application number
MA046959A
Other languages
English (en)
Inventor
Hyam I Levitsky
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MA46959A publication Critical patent/MA46959A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
MA046959A 2016-12-02 2017-11-30 Cellules b modifiées et compositions et méthodes associées MA46959A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662429709P 2016-12-02 2016-12-02

Publications (1)

Publication Number Publication Date
MA46959A true MA46959A (fr) 2019-10-09

Family

ID=60915605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046959A MA46959A (fr) 2016-12-02 2017-11-30 Cellules b modifiées et compositions et méthodes associées

Country Status (7)

Country Link
US (1) US11793833B2 (fr)
EP (1) EP3548622A1 (fr)
CN (1) CN110494565A (fr)
AU (1) AU2017367695A1 (fr)
CA (1) CA3045323A1 (fr)
MA (1) MA46959A (fr)
WO (1) WO2018102612A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7275043B2 (ja) 2016-12-16 2023-05-17 ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2019046815A1 (fr) * 2017-08-31 2019-03-07 Poseida Therapeutics, Inc. Système de transposon et procédés d'utilisation
EP3768707A4 (fr) * 2018-03-19 2022-01-26 The Invention Science Fund II, LLC Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués
CN112912389B (zh) * 2018-06-19 2024-04-19 H·李·莫菲特癌症中心和研究所公司 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗
CN112543808A (zh) 2018-06-21 2021-03-23 比莫根生物科技公司 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法
US12440513B2 (en) 2019-03-22 2025-10-14 Albany Medical College Methods for improving cognitive function
WO2020206046A1 (fr) * 2019-04-01 2020-10-08 The Broad Institute, Inc. Procédés et compositions pour thérapie cellulaire
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
WO2020243458A1 (fr) * 2019-05-29 2020-12-03 H. Lee Moffitt Cancer Center And Research Institute Inc. Lymphocytes b thérapeutiques modifiés pour exprimer des anticorps engageurs de lymphocytes t bispécifiques
WO2020257408A1 (fr) * 2019-06-18 2020-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lymphocytes b producteurs d'interleukine-27 et leurs utilisations
EP4028413A1 (fr) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Protéines de fusion de ca2-il15 pour une régulation accordable
KR20220107019A (ko) * 2019-11-27 2022-08-01 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 B 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집
CN115427579A (zh) * 2019-12-17 2022-12-02 阿瑞迪思医药公司 增强和加速抗体表达的方法
EP4084815A1 (fr) * 2020-01-02 2022-11-09 Edity Therapeutics Ltd. Compositions et méthodes d'administration
EP4127188A4 (fr) 2020-03-31 2024-08-21 Walking Fish Therapeutics Lymphocytes b modifiés et méthodes pour les utiliser
CN116323920A (zh) 2020-08-07 2023-06-23 荷兰商新基因治疗公司 富集基因工程t细胞的方法
CN114539357B (zh) * 2020-11-27 2024-07-30 广州汉腾生物科技有限公司 信号肽在表达glp-1融合蛋白中的应用
JP2024503515A (ja) * 2021-01-20 2024-01-25 ネオジン セラピューティクス ビー．ブイ． 改変抗原提示細胞
TW202332456A (zh) * 2021-10-06 2023-08-16 美商步行魚醫療公司 以經修飾之ｂ細胞來增強ｔ細胞活性之方法及組成物
WO2024151683A2 (fr) * 2023-01-09 2024-07-18 Walking Fish Therapeutics, Inc. Lymphocytes b humains modifiés pour exprimer des anticorps iga et igm pour une utilisation thérapeutique
JP2026505562A (ja) * 2023-02-14 2026-02-13 ビー バイオファーマ， インコーポレイテッド 細胞保存の方法
WO2024238710A1 (fr) * 2023-05-16 2024-11-21 Be Biopharma, Inc. Compositions et procédés de production de cellules immunitaires modifiées
WO2024249320A1 (fr) * 2023-05-26 2024-12-05 University Of Florida Research Foundation, Incorporated Optimisation in vivo de produits biologiques
WO2025024776A2 (fr) * 2023-07-27 2025-01-30 Duke University Compositions comprenant des fragments xbp1 et méthodes d'utilisation en thérapie génique
US20250152714A1 (en) * 2023-11-15 2025-05-15 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DK0557459T3 (da) 1990-11-13 1997-12-15 Immunex Corp Bifunktionelle, selekterbare fusionsgener
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997012052A1 (fr) 1995-09-28 1997-04-03 Targeted Genetics Corporation Transduction de cellules hematopoietiques par vecteur viral et lipide cationique
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
CA2309313A1 (fr) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation de la reponse immunitaire par manipulation des cellules dendritiques humaines
CA2394850C (fr) 1999-12-06 2012-02-07 Sangamo Biosciences, Inc. Procede d'utilisation de banques de proteines a doigt de zinc randomisees, pour l'identification d'une fonction de genes
EP1254369B1 (fr) 2000-02-08 2010-10-06 Sangamo BioSciences, Inc. Cellules destinees a la decouverte de medicaments
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2003016496A2 (fr) 2001-08-20 2003-02-27 The Scripps Research Institute Domaines de fixation en doigt de zinc pour cnn
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20040029271A1 (en) * 2002-05-08 2004-02-12 Boehringer Ingelheim International Gmbh Pax5-deficient pro-B cells, methods of producing them and the use of such cells in human therapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4903689B2 (ja) 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
BRPI0619579B8 (pt) 2005-12-09 2022-01-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
DK2433713T3 (en) 2007-12-07 2017-09-25 Miltenyi Biotec Gmbh CELL PROCESSING SYSTEMS AND PROCEDURES
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP4032552B1 (fr) 2008-08-26 2023-10-04 City of Hope Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
WO2010059876A2 (fr) 2008-11-21 2010-05-27 California Institute Of Technology Système de culture de lymphopoïèse de lymphocytes b humains in vitro
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
WO2011147622A1 (fr) * 2010-05-26 2011-12-01 Deutsches Rheuma-Forschungszentrum Berlin Lymphocytes b naïfs présentateurs d'antigènes modifiés pour la suppression immunitaire et procédé de fabrication desdites cellules modifiées
DK2646466T3 (en) 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
CN110684745A (zh) 2011-07-27 2020-01-14 韦克塔里斯公司 可用于转导真核细胞的基于病毒的载体组合物
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) * 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150216903A1 (en) 2012-08-10 2015-08-06 Bluebird Bio, Inc. Compounds for improved viral transduction
KR102264290B1 (ko) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
CN112458057A (zh) 2012-10-02 2021-03-09 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
US20160033504A1 (en) 2013-03-15 2016-02-04 Alder Biopharmaceuticals, Inc. Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015148879A1 (fr) 2014-03-27 2015-10-01 The Regents Of The University Of Michigan Compositions d'immunothérapie du cancer et méthodes associées
EP3234107B1 (fr) 2014-12-19 2022-09-14 Immusoft Corporation Lymphocytes b pour l'administration in vivo d'agents thérapeutiques
ES2959608T3 (es) 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
WO2018175390A1 (fr) 2017-03-20 2018-09-27 Washington University Cellules et méthodes d'utilisation et de production de celles-ci

Also Published As

Publication number Publication date
EP3548622A1 (fr) 2019-10-09
US11793833B2 (en) 2023-10-24
US20190321403A1 (en) 2019-10-24
WO2018102612A1 (fr) 2018-06-07
AU2017367695A1 (en) 2019-06-13
CN110494565A (zh) 2019-11-22
CA3045323A1 (fr) 2018-06-07

Similar Documents

Publication Publication Date Title
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
EP3471772A4 (fr) Compositions et méthodes de déplétion de cellules
EP3600325A4 (fr) Nouvelles compositions et méthodes
IL269334A (en) Improved t cell compositions and methods
EP3472305A4 (fr) Cellules treg génétiquement modifiées
IL262772A (en) Genetically engineered cells and methods of making the same
EP3436083A4 (fr) Nouvelles compositions et méthodes
EP3380117A4 (fr) Cellules génétiquement modifiées et utilisations de ces dernières
EP3694869A4 (fr) Méthodes et compositions de sélection transgénique
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
IL254734B1 (en) Modified t cells and methods of making and using the same
PL4074331T3 (pl) Kompozycje i sposoby internalizacji enzymów
KR20180084891A (ko) 구조 조성물 및 방법
PT3212225T (pt) Métodos e composições para células t modificadas
EP3523416A4 (fr) Méthodes et compositions associées à des thérapies anticancéreuses de cellules nk et anti-pdl1
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
DK3274430T3 (da) Mikroalgesammensætninger og deres anvendelser
PL3394259T3 (pl) Kompozycje i sposoby zmniejszania ekspresji tau
EP3455344A4 (fr) Cellules souches/progénitrices hématopoïétiques
EP3273950A4 (fr) Compositions adjuvantes et méthodes associées
EP3503879A4 (fr) Compositions et procédés associés
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
IL256322B (en) Improved formulations of deferasirox and methods of making the same
EP3384038A4 (fr) Méthodes et compositions pour la reprogrammation de cellules